
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics is supported by a strong commercial foundation as Auvelity delivered $207.6M in 3Q26 revenue, up 53% year over year and in line with consensus, while prescriptions rose to about 302,000 and gross-to-net improved into the mid-to-high 40s. The newly approved Alzheimer’s agitation launch is gaining traction with 65+ TRx up 101% year over year and 43% quarter over quarter, suggesting a second large indication with limited competition and broad Medicare access, while Sunosi and Symbravo add steady incremental revenue. With $313.9M in cash, manageable operating expenses, and a pipeline of de-risked CNS programs including AXS-12 and solriamfetol catalysts, the company appears positioned for continued growth and cash flow positivity.
Bears say
Axsome Therapeutics is viewed negatively because its valuation is highly dependent on Auvelity while multiple pipeline assets face meaningful regulatory, clinical, and commercial execution risk. The company’s own downside case highlights that slower conversion of sampled ADA patients, payer coverage gaps, generic step-throughs, and strong competition in CNS categories could limit uptake, with Sunosi sales at $33.8M in 2Q26 and Symbravo revenue only $2.3M amid shrinking net revenue per script. AXS-14 also remains uncertain after the June 2025 Refusal to File, and the broader portfolio carries financing and dilution risk, making durable revenue growth difficult to underwrite.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Axsome Therapeutics (AXSM) Forecast
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares